City and hospital collaboration to find early liver fibrosis in the Grenoble area
Official title: City-Hospital Collaboration for Early Detection of Liver Fibrosis in Primary Care: A Secondary Prevention Project in the Grenoble Health Area
Run by University Hospital, Grenoble · NCT07031089 · Data updated 2026-11-12
This project tests using a simple FIB‑4 blood score followed by a FibroScan to find early liver fibrosis in adults referred by their primary-care doctor in the Grenoble area.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 2 sites (Grenoble and 1 other locations) |
| Status | Recruiting |
| Started | January 14, 2026 |
| Main results expected | August 14, 2028 |
| Study ends | January 14, 2029 |
| Registry record updated | March 2, 2026 |
| Trial ID | NCT07031089 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older who were referred by a general practitioner or authorized primary-care provider, had FIB‑4 > 1.3, and underwent FibroScan at CHU Grenoble-Alpes or CPTS-SEG between January 2023 and January 2026 with a result ≥ 8 kPa are the intended participants.
✕Probably not a fit
People already known to have chronic liver disease and already under specialist follow-up, those with FibroScan < 8 kPa, or those legally unable to consent (under guardianship or deprived of liberty) are unlikely to benefit from this screening project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational secondary-prevention project follows adults referred by primary-care providers for liver fibrosis screening using the FIB‑4 score and transient elastography (FibroScan). Eligible participants are adults who had FIB‑4 > 1.3 and underwent FibroScan at CHU Grenoble-Alpes or CPTS-SEG between January 2023 and January 2026, with FibroScan results ≥ 8 kPa. The work documents how often advanced fibrosis is detected in this real-world primary-care pathway and how patients are routed to hospital care. The protocol is non-interventional and uses routine clinical data to measure detection rates and referral patterns.
Why it matters
Potential benefit: If successful, the program could catch advanced fibrosis earlier so patients can get timely follow-up and treatment to reduce progression to cirrhosis and liver cancer.
How similar studies have gone: Previous programs using FIB‑4 followed by transient elastography in primary care have successfully identified patients with advanced fibrosis, though implementation and follow-up vary by region.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 years or older * Having undergone a Fibroscan® at the CHU de Grenoble-Alpes or CPTS-SEG, requested by a primary care practitioner (general practitioner, non-hospital diabetologist, Asalée nurse), as part of the screening recommendations for liver fibrosis in the case of a FIB4 score \> 1.3 * With a result ≥ 8kPa * Between January 2023 and January 2026 Exclusion Criteria: * Patients who have expressed their opposition to participating in the study * Patients under guardianship or deprived of liberty * Patients with a known chronic liver disease who are being monitored at the time of the Fibroscan® procedure
Where it's running
-
Grenoble Alpes University Hospital
Grenoble, France Recruiting -
Communauté Professionnelle Territoriale de Santé Sud Est Grenoblois
Grenoble, France Not yet recruiting
Study contacts
- Study coordinator: Anna Borowik, PhD
- Email: aborowik@chu-grenoble.fr
- Phone: +33476769314
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Endohepatology-based reclassification of treatment indication in high-risk MASLD
This study tests whether an endohepatology assessment can change treatment decisions for adults with high-risk MASLD.
-
Umbilical cord stem cells added during Kasai to help biliary atresia
This early-stage trial tests whether injecting umbilical cord mesenchymal stem cells during Kasai portoenterostomy is safe and helpful for infants with biliary atresia.
-
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD
This program automatically screens high‑risk adults aged 50–75 in primary care to see if they have advanced liver fibrosis and possible MASLD, using routine blood tests and reflex lab tests without extra work for clinicians.
-
AZD2389 safety and dosing in adults with fatty liver disease and advanced liver scarring
This study tests whether AZD2389 is safe and how it behaves in adults with steatotic liver disease and advanced fibrosis, comparing it to placebo over about six months.
-
See if EUS-SWQ can accurately detect and grade liver fibrosis in adults with chronic liver disease
This study tests whether the endoscopic ultrasound shear wave quantification (EUS-SWQ) can match liver biopsy results in adults with chronic liver disease to diagnose and stage fibrosis, and whether it offers safety and measurement advantages over FibroScan.
-
Non-invasive liver fibrosis testing in children and young adults with type III glycogen storage disease
This project tries to see if non-invasive liver stiffness measurements (like elastography) can monitor liver fibrosis in children and young adults with type III glycogen storage disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.